arginase/infarction

The study is performed on one group of patients with type 2 diabetes and one group of age-matched healthy controls Inclusion criteria: 1. Type 2 diabetes 2. Poor glycaemic control defined as a mean day blood glucose >12 mmol/L. Exclusion criteria: 1. Age >80 years. 2. HbA1c <70 mmol/mol 3.

Background: Arginase competes with nitric oxide synthase for their common substrate L-arginine. Up-regulation of arginase in coronary artery disease (CAD) and diabetes mellitus may reduce nitric oxide bioavailability contributing to endothelial dysfunction and ischemia-reperfusion injury. Arginase

Adverse clinical outcomes are reduced when critically ill patients are only transfused if their hematocrit drops below 21%: Hematocrit (HCT) is a measure of the severity of anemia. A HCT is considered normal if it ranges between 38 and 48% of total blood volume. In critically ill patients anemia is